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Abstract
This paper investigates the determinants of regional variations in outpa-
tient antibiotic consumption using Swiss data. The analysis contributes to
the debate on appropriate antibiotic use by improving the understanding of
its determinants, and may help to define more eﬀective health care policies to
reduce the resistance phenomenon. Findings suggest that Switzerland exhibits
relatively low levels of consumption among European countries. There are sig-
nificant diﬀerences between cantons both in the per capita antibiotic sales and
defined daily doses per 1000 inhabitants (DID). Econometric estimations sug-
gest that DID are significantly related to per capita income, antibiotic price,
the density of medical practices, demographic, cultural and educational fac-
tors. The incidence of bacterial infections is also relevant. Appropriate policies
aﬀecting antibiotic consumption in the community can be designed by looking
at crucial determinants in the model and their related impact.
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1 Introduction
The consumption of antibiotics has rapidly increased during the past 50 years. An-
tibiotics have significantly contributed to the reduction in the likelihood of dying from
infectious diseases worldwide (WHO, 2000; 2001). However, researchers suggest that
almost one third of drug prescriptions are questionable (Wise et al., 1998; Homer et
al., 2000).
Between 1980 and 1991 most European countries experienced an increase in the
number of antibiotic prescriptions. The growth rate of consumption was about 45%
for England, 65% for France and almost 80% for Germany. According to Davey
(1996) a partial explanation is represented by the increasing use of antibiotics for res-
piratory symptoms. Antibiotic prescriptions have slightly decreased during the 90s
but prescribing practices still vary widely across countries (Goossens et al. 2005). For
instance, the percentage of antibiotic prescriptions for colds and tonsillopharyngitis
between 1980 and 1991 were respectively 48.7% and 94.6% in France versus 7.7% and
69.6% in Germany (Bouvenot, 1999). During the same period the French consump-
tion of antibiotics for respiratory infections with presumed viral origin increased by
around 115% for children and 86% for adults (Guillemot et al., 1998). Mousquès et
al. (2003) suggested that a change in physicians’ behaviour may at least partially
explain the large amount of prescriptions for acute rhinopharyngeal infections: there
is a tendency to prescribe the most recent and the most costly antibiotics such as
cephalosporins.
In the USA the use of broad spectrum antibiotics and prescriptions of antibiotics
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for common viral diseases such as upper respiratory tract infections increased during
the 90s (Steinman et al., 2003). Antibiotic prescription rates respectively for people
with colds, URIs, and acute bronchitis was 46%, 47%, and 60% in 1996 (Cantrell
et al., 2002). McCaig et al. (2003) showed that on average 45% of the population
received antibiotics in 2000. The analysis of Cantrell et al. suggests that around
11 millions of prescriptions in the USA are inappropriate and estimates a waste of
health care resources up to $281 millions.
Antibiotic consumption may not be optimal because of multiple market imper-
fections. First, patients may not face the marginal cost of drugs when making their
consumption choices. Consumers have an incentive to purchase more drugs than
they would if insurance was not available (Newhouse, 1993). Second, the individual
production function of health is characterized by uncertainty. Although antibiotics
are not eﬀective in treatments of viral diseases, patients’ lack of knowledge and ex-
perience may increase inappropriate consumption. Indeed, studies have shown that
doctors decisions to prescribe antimicrobials are related to patients’ expectations.
Under time pressure, doctors tend to satisfy their patients and to avoid follow up
visits (Butler et al., 1998). Third, marginal social benefits from consumption may
not reflect marginal private benefits. Marginal private benefits from consumption
may not internalize external benefits derived from one’s treatment with antibiotics
which reduces the probability of infection spreading to other individuals (Elbasha,
2003). Finally, over consumption of antibiotics may contribute to the selection of
resistant bacteria, and hence, reduce their eﬀectiveness (McGowan, 2001). Marginal
social costs of antibiotic usage may then not reflect marginal private costs since the
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latter do not consider the costs of reduced antibiotic eﬀectiveness due to bacterial
resistance (Levy, 1998; Coast et al., 1998). Because of resistance, antibiotics be-
come a scarce resource and it is in the interest of the society as a whole to preserve
their eﬀectiveness (Laxminarayan and Weitzman, 2002; Rowthorn and Brown, 2003;
Rudholm, 2002).
The investigation of regional variations in antibiotic use may contribute to the
debate on appropriate antibiotic use by improving the understanding of its determi-
nants. Moreover, the analysis may help to define more eﬀective health care policies
to reduce the resistance phenomenon.
Diﬀerences between geographical areas may be explained by demographic, cul-
tural, and socioeconomic factors. However, it is hard to believe that physicians
and/or patients in diﬀerent areas will not vary in their preferred treatment practices
for health conditions where alternative treatments are available and where the na-
ture of the infection exhibits substantial uncertainty. Researchers suggest that the
investigation of small geographical areas may bring out the role of health care sup-
ply organizational factors compared to demand variables (Wennberg and Gittelsohn,
1982).
The literature lacks empirical investigation of within country variations in antibi-
otic use. Moreover, studies focusing on international comparisons between countries
use a descriptive statistics approach rather than applying econometric techniques to
explain the determinants of cross-country variations (Bremon et al. 2000).
The paper intends to investigate regional variations in outpatient antibiotic use
in Switzerland, to estimate the cantonal demand for antibiotics and study the impact
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of critical factors. In section 2 we compare outpatient antibiotic sales in Switzerland
with other European countries and investigate cantonal diﬀerences within the country.
In section 3 we estimate the cantonal demand for outpatient antibiotics and discuss
its determinants. Section 4 concludes.
2 Variations in antibiotic consumption
2.1 Outpatient antibiotic use in Switzerland
In this section, we investigate outpatient antibiotic utilization in Switzerland and
compare it with use in other European countries. We consider both total use in
terms of defined daily doses per 1000 inhabitants per day (DID)1 and sales per capita.
Swiss sales data were provided by IHA-IMS Health. Defined daily doses per 1000
inhabitants daily and sales per capita were calculated using additional demographic
information and WHO standard doses (we refer the reader to section 3.2 for further
details on data).
Figure 1 is constructed by using data from the European Surveillance of Antimi-
crobial Consumption (ESAC I) project and by including new data from Switzerland.
The ESAC project collected either reimbursement data or distribution/sales data
depending on the method for measuring antibiotic use employed by each national
database. Antibiotic sales, prescribing and consumption are then used interchange-
ably in the European study although concepts are not exactly the same. Patients
may systematically lack compliance either because they badly tolerate the treat-
ment or because symptoms have resolved. Moreover, as suggested by Cizman (2003),
1The defined daily dose (DDD) measurement unit is based upon the WHO version 2003.
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physicians may overprescribe antibiotics to meet patient’s expectations or to reduce
misdiagnosis of bacterial infections. As a result prescribing data may overestimate
antibiotic consumption. As for wholesales to dispensing pharmacies, doctors and
drugstores, these may not match prescribing data if drugs can also be purchased
without any prescription. However, this is unlikely to happen for antibiotics. A
mismatch between wholesales and prescribing data may derive instead from seasonal
fluctuations of retailers’ stocks of drugs due, for instance, to unexpected variations in
the incidence of infections. In our analysis we will also ignore the possible mismatches
between antibiotic sales and antibiotic consumption and use either one term or the
other interchangeably.
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Figure 1: Outpatient antibiotic use per country including Switzerland (2002).
Sources: ESAC and IHA-IMS.
Large diﬀerences in outpatient antibiotic consumption are observed across Euro-
pean countries (Cars et al. 2001 ; Goossens et al., 2005). Relatively high consumption
defined in daily doses per 1000 inhabitants per day (DID) are observed in France,
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Greece, Luxembourg, Portugal, and Italy, among others. On the contrary, Austria,
Estonia, Germany, Latvia, and the Netherlands, for instance, exhibit significantly
lower values. Median European consumption of antibiotics in ambulatory care in
2002 is 18.8 DID. The greatest consumption (32 DID) is attained by France. Outpa-
tient antibiotic use in Switzerland measured in DDDs per 1000 inhabitants daily is 9
DID, below the Dutch level of 9.8 DID.
The ranking obtained by ordering European countries as with respect to DDDs
per 1000 inhabitants per day in 2002 suggests that Switzerland is indeed the country
with the lowest antibiotic consumption in the community.
Not surprisingly, this is in accordance with the 2003 OECD statistics (OECD,
2003) suggesting that Switzerland is among countries with low consumption rates of
pharmaceuticals. Among possible explanations is the combination of organizational
aspects of the health care system based upon private health insurances and physicians’
and patients’ attitude towards the use of drugs. The combination of deductible and
direct payments may contribute to the prevention of moral hazard behavior. Swiss
physicians and patients may either be more aware of the implications of antibiotic
consumption, such as bacterial resistance, and face tighter financial incentives. The
health economics literature suggests that pure fee-for-service payment schemes, akin
to the Swiss one, may increase the volume of services provided compared to capitation
regimes. However, the incentive to reduce workload by increasing prescriptions may
be lower (see Scott, 2000).
As shown in figure 2, total antibiotic consumption in ambulatory care in Switzer-
land has been roughly stable over the three years considered. Consumption has
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slightly increased in 2003 (9.5 DID) but decreased in 2004 (9.3 DID).
40.5% 42.5% 43.5%
8.7%
8.4% 8.9%
8.4%
8.3% 8.9%
16.8%
16.1% 14.9%
20.1%
19.7% 19.5%
0
3
6
9
12
2002 2003 2004
D
D
D
 p
er
 1
00
0 
in
ha
bi
ta
nt
s 
pe
r d
ay
Penicillins J01C Cephalosporins J01D Tetracyclines J01A Macrolides J01F
Quinolones J01M Sulfonamides J01E Others 
Figure 2: Structure of outpatient antibiotic consumption in Switzerland (2002-2004).
Looking at the consumption structure, the literature suggests that there is wide
variation in the proportion of diﬀerent classes of antibiotics between countries (Bergan,
2001; Cizman 2003). isThe Swiss share of quinolones is 20.1% of total consumption in
2002. Although the Swiss use of quinolones is not far from the European average (1.8
DID against 1.4 DID), Switzerland uses this category of antibiotics in the commu-
nity in much higher proportions (the European average share of quinolones without
Switzerland is 7.3%). This implies that Switzerland uses relatively lower proportions
of others classes of antibiotics compared to European countries.
The use of penicillins has slightly increased over time (from 40.5% in 2002 to 43.5%
in 2004). The Swiss consumption of penicillins is below the European average both in
terms of DID and the share on total consumption (3.7 DID and 40.5% compared to 8.7
8
12%
24%
63%
1%
Narrow  spectrum penicillins J01CE
Broad spectrum penicillins J01CA
Comb. w ith Beta-lactamase inhibitors J01CR
Beta-lactamase resistant penicillins J01CF
Figure 3: Penicillins composition in Switzerland (2002).
DID and 46.4%). Looking at penicillins in more details, we observe that combinations
with β-lactamase inhibitors represents 63% of total consumption of penicillins (figure
3). This proportion is similar to the proportion used in Belgium and Portugal, for
instance, and above the European average
Similar figures can be observed for cephalosporins and macrolides. The Swiss
consumption for the former category is 0.8 DID (8.7%) whereas the European average
is 1.9 DID (10.2%). In the latter category Switzerland consumes 1.5 DID (16.8%)
compared to the European average of 2.7 DID (14.3%).
The ranking of Switzerland between European countries in terms of per capita
consumption for diﬀerent classes of antibiotics can then vary. Switzerland is 18th out
of 27 European countries for the consumption of cephalosporins, and the 5th least
consuming country for macrolides. On the other side, Switzerland is the 8th larger
consumer of quinolones.
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It is worth noticing that the comparison of Swiss consumption data with those
of other European countries as well as between the European countries of the ESAC
study requires a bit of carefulness. There may be diﬀerences related to the collection
of data since not all of the countries derive data from the same source. These may
either come from the distributional channel or the reimbursement registrations which
may not perfectly match. Moreover, outpatient antibiotic consumption may either
include or exclude antibiotic used in nursing homes. Nursing homes are generally
counted in outpatient antibiotic consumption of most European countries although
for few of them they are included in the hospital consumption.
2.2 Cantonal diﬀerences
Switzerland is a federal state made of 26 cantons. Cantons generally diﬀer not only
with respect to geographical characteristics, but also for cultural and socioeconomic
aspects of the population and the organization of the health care system. The anal-
ysis of cantonal diﬀerences in antibiotic consumption may then reflect these aspects
besides epidemiological ones. We investigate cantonal antibiotic use in terms of sales
(in CHF) per capita and DDDs per 1000 inhabitants daily using yearly data from
2002 to 20042.
The average cantonal expenditure in 2002 was around CHF 12 per capita with a
standard deviation of 3.72. The expenditure varies from a minimum of CHF 6.44 to a
maximum of CHF 22.63. Average per capita expenditure has increased between 2002
and 2003 by 3.2% and decreased afterwards by 4.5%. Diﬀerences between cantons
2In the analysis which follows 5 small cantons have been aggregated into 2 bigger regions (see
section 3.2 for further details).
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appear to be significantly large all over the three years.
In terms of DDDs per 1000 inhabitants per day, the average cantonal outpatient
antibiotic consumption was 9 DID in 2002 (figure 4). Average antibiotic use has
slightly increased in 2003 and then reduced to 9.3 DID in 2004. Hence, average
individual consumption daily has been roughly stable over the three years. Note,
however, the wide diﬀerences between cantons. These can be summarized by the
variation coeﬃcient3: 29 in 2002, 26 in 2003, and 26 in 2004. Given a minimum
cantonal consumption of 4.7 DID in 2002 (AR - Appenzell Rhodes), the highest
consumption is more than 3 times greater (15.6 DID for GE - Geneva). Similar
figures are observed for 2003 (min. 5.3 DID - Max. 16 DID) and 2004 (min. 5.3 DID
- Max. 15.4 DID). Median values were 7.7 DID in 2002 (ZH - Zurich), 8.3 DID in
2003 and 2004 (SO - Solothurn and Zurich).
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Figure 4: Oupatient antibiotic use per canton.
3The variation coeﬃcient is the ratio between the standard deviation and the mean multiplied
by 100.
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Although there are substantial cantonal diﬀerences in all of the three years ob-
served, the variation coeﬃcient indicates that diﬀerences has slightly reduced over
time. In 2003 the big majority of cantons have increased antibiotic use expressed in
DDDs per 1000 inhabitants daily but two cantons (VD - Vaud and OW - Obwalden)
have reduced consumption. On average, consumption has increased by 5.6%. How-
ever, cantons such as St. Gall (SG) and Grisons (GR) exhibit more substantial
growth. The t-test on the mean equality between 2002 and 2003 confirms that can-
tonal consumption has significantly increased. In 2004 average outpatient antibiotic
consumption expressed in DID has decreased by 2.7% compared to 2003. The reduc-
tion characterizes all cantons with the exception of Zurich.
Looking more carefully at figure 4, we note that cantons with the highest con-
sumption (such as Geneva, Vaud, Neuchatel andValais) are generally located in the
South-West part of Switzerland. Conversely, cantons with the lowest consumption
are located North-East in the country.
Cantonal antibiotic consumption can be disaggregated by main antibiotic classes
(figure 2). We summarize the following 6 categories as previously done for the whole
Switzerland: penicillins, cephalosporins, tetracyclines, macrolides, quinolones, and
sulfonamides. Cantonal diﬀerences can be observed in the structure of total con-
sumption (figure 5). The proportion of penicillins use is between a minimum of 33.5%
in Obwalden and a maximum of 44.8% in Solothurn. Macrolides range from 12.7%
to 22.1% whereas quinolones vary from 17.2% to 23.1%. Although there are clearly
diﬀerences in the cantonal consumption structure, figures suggest that within country
variations are less substantial compared to those observed across European countries
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(see Goossens et al., 2005). Cantonal diﬀerences in terms of the proportion of each
antibiotic category on total consumption may be related to local variables such as the
prevalence of infections, patients’ and doctors’ preferences, pharmaceutical marketing
strategies, cantonal regulation, and the incidence of bacterial resistance.
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Figure 5: Structure of antibitic consumption in the community per canton.
3 Explaining variations
Regional variations in antibiotic consumption may be explained by a variety of factors.
Several authors have suggested that doctors’ decision to prescribe and patients’ use
of antibiotics are explained not only by clinical factors and by diﬀerences in bacterial
infections across regions. Diﬀerence in bacterial infection can hardly explain variation
in morbidity as large as four fold among industrialized countries. The literature has
suggested the lack of education, physicians and patients’ expectations, uncertainty,
cultural and social behavior, and diﬀerences in regulatory practice, among other
13
factors (Belongia and Schwatz, 1998; Finch et al. 2004).
Previous studies focusing on the determinants of antibiotic consumption have
been conducted either in the form of trials or questionnaire surveys. Mecfarlane et
al. (2002) investigated the impact of patient’s information. Their experiment showed
that the distribution of information leaflets to patients not in need for antimicrobials
eﬀectively reduced their use without aﬀecting the doctor-patient relationship. Using
a questionnaire survey on 22 Australian non-randomly selected general practitioners
and 336 patients, Cockburn and Pit (1997) showed that patients expecting a medi-
cation were nearly three times more likely to receive it compared to other patients.
Moreover, patients were ten times more likely to receive a medication if practitioners
perceived a patient’s expectation on prescribing. Doctors’ perception and patients’
expectations were significantly associated to each other. Webb and Lloyd (1994) sug-
gested that older people are more likely to be prescribed a medication, although this
result is not confirmed by Cockburn and Pit’s study. Harbarth et al. (2002) suggested
that large diﬀerences in antibiotic consumption between France and Germany are at
least partially related to diﬀerences in the concentration of child care facilities and
the use of breast feeding between the two countries. Finally, Unsworth and Walley
(2001) showed that antibiotic prescribing is related to practice characteristics in the
British NHS. Deprived and single-handed practices tend to prescribe more but cheap
antibiotics, while dispensers and trainers, with low level of deprivation and early wave
fundholders have lower rate of prescriptions.
An alternative approach to investigate the determinants of antibiotic consump-
tion is to use regional consumption data and regress them against a set of variables
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suggested by the literature as plausible causal factors of the demand for drugs. This
approach is applied, for instance, by Di Matteo (2005) to investigate the macro deter-
minants of health expenditure in the United States and Canada. We apply a similar
approach to regional outpatient antibiotic consumption in Switzerland and discuss it
in the following section.
3.1 An econometric approach
From the economic point of view, antibiotics are an input of the health care and the
health production process. Therefore, following the Grossman’s tradition it is possible
to derive the demand for antibiotics directly from the demand for health care. In this
framework, the demand for antibiotics is a demand derived from the demand for
healthy days and can be specified using the basic framework of household production
theory4. In this framework, a household combines drugs, health care, time, exercise,
education and capital equipment to produce healthy days.
Inspired by this approach and given the restriction of aggregate data5, it is possible
to specify an ad-hoc demand function for the cantonal per capita outpatient antibiotic
consumption, where the demand for antibiotics depends on the individual’s stock of
health care (H), income (Y ), prices of antibiotics and prices of other health care
services, the incidence of infectious diseases and other socioeconomic variables such as
age, nationality and education.6 These socioeconomic variables are usually included
4For a precise presentation of the household production theory, see Becker (1965). See also
Grossman (1972) for an application of household production theory to health care.
5An alternative approach would be to use more disagreggated data even at individual level.
However, such a dataset was not available.
6Of course, we are aware that the use of aggregated data to explain individual antibiotics con-
sumption implies the assumption that the hypothesized relationship between the economic variables
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in the model as proxies for the individual stock of health care, which is diﬃcult to
measure. Moreover, under a pure fee-for-service reimbursement scheme, there may
be incentives to induce the demand for physicians’ services7. Thus, the demand for
antibiotics could also depend on some characteristics of the supply of health care
services as physicians’ density.
Taking into account the availability and the quality of data for the Swiss cantons,
we first specify the following parsimonious empirical model (Model 1) for the per
capita demand of outpatient antibiotics:
DIDit = f(Yi, Pit,DPHi, UNDER20i, OV ER65i, FOi, EDUi,
INFi, DLATIN,DTt), (1)
where DIDit are per capita antibiotic sales in canton i and quarter t, measured in
defined daily doses, Yi is the cantonal per capita income, Pit is the price of a de-
fined daily dose, DPHi is the cantonal physicians’ density, OV ER65i indicates the
percentage of the population older than 65, UNDER20i is the percentage of the
population below 20, FOi is the share of foreigners on total population and EDUi
is the percentage of individuals without post-mandatory education. The incidence of
infections (INFi) is taken into account by the number of campylobacter infections
per 100,000 inhabitants per year. As stressed by Lederberger et al. (2003), campy-
lobacter is a major cause of foodborne bacterial gastrointestinal human infections in
Switzerland.8 A “cultural” dummy (DLATIN) that takes into account similarities
in question is homogeneous across all individuals. Therefore, using this aggregate data set at the
cantonal level we could encounter an aggregation bias.
7For a summary reading of the supply-induced demand theory see McGuire (2000).
8Streptococcus pneumonie was also an important bacteria responsible for the large majority of
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with adjacent countries and cultural diﬀerences across Switzerland is also included.
Lecomte and Paris (1994) suggested that socio-cultural factors which are hard to
measure might explain diﬀerences in consumption patterns between European coun-
tries. For instance, they underline the relevance of the medical training since German
students are more likely to learn homoeopathic principles whereas UK students are
more likely to recognize the importance of primary care. We divided cantons in two
groups: “Latin”, “non-Latin”. The “Latin” group includes French and Italian speak-
ing cantons (GE, VD, NE, FR, VS, TI, JU) whereas “non-Latin” includes German
speaking cantons (BS, BL, BE, SG, ZH, SO, AG, SZ, GL, LU, GR, ZG, TG, OW, SH,
AR).9 Finally, DTt is a dummy variable to control for seasonal eﬀects of antibiotic
use. This takes value equal to 1 for period t (t = 1, 2, 3, 4); otherwise is 0.
Estimation of equation (1) requires the specification of a functional form. Several
alternative forms could be considered since the theory of demand is quite ambiguous
regarding this issue. The log-log specification oﬀers an appropriate functional form
for investigating the responsiveness of antibiotic sales to changes in a number of
explanatory variables. The major advantage is that the estimated coeﬃcients can
be interpreted as elasticities10, which are, therefore, assumed to be constant. By
respiratory tract infections and a good candidate as an indicator of the incidence of infections. Since
data on campylobacter infections appear to be more reliable than data on streptococcus infections
we used the former as an explanatory variable in our models.
9Looking at the values of the partial correlation coeﬃcient between the explanatory variables
and the dependent variable we observe some variables with a negative sign, Y (-0.14), P (-0.27)
and UNDER20 (-0.33) and some variables with a positive sign, OVER65 (0.13), DPH (0.62), EDU
(0.08), FO (0.54), INF (0.13), DLATIN (0.7).
10This means that coeﬃcients represent the percentage change in the value of the explained
variable corresponding to a one percent variation in the value of the explanatory variable.
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applying the log-log functional form, the model (Model 1) can be written as:
lnDIDit = β0 + β1 lnYi + β2 lnPit + β3 lnDPHi + β4 lnUNDER20i
+β5 lnOV ER65i + β6 lnFOi + β7 lnEDUi + β8 ln INFi
+β9DLATIN + β10DT1 + β11DT2 + β12DT3 + εit, (2)
where ln() is a natural logarithm applied to the variable.
However, since prices and the number of infections are plausibly endogenous,
the estimation of equation (2) may lead to biased results. To tackle this problem we
consider two alternative approaches: the inclusion of lagged values (Model 2 ) and the
instrumental variable method (Model 3). In Model 2 instead of Pit we use Pit−1 - the
lagged price of a defined daily dose -, and instead of INFi we useMEANINFi - the
average number of infections calculated over the years 1999-2001 -. The estimation
of Model 1 and Model 2 was carried out by using an OLS estimation procedure and
a GLS estimation procedure for pooled time-series and cross-sectional data suggested
by Kmenta (1986).11
If the spread of a disease is a dynamic process an instrumental variable may
be preferred. Thus, we specify a model (Model 3) by instrumenting the number
of campylobacter infections (INFi) with the average number of infections over the
past three years (MEANINFi) and three additional variables: the density of the
11From the econometric point of view, we should consider that our panel data set is characterized
by a relatively small number of time periods, a limited number of cross-sectional units and a zero
within variation for most of the explanatory variables. The only two variables that are changing over
time are the outpatient per capita consumption and the price of an antibiotic daily dose. Hence,
the least squares dummy variable model and the error components model are not appropriate. For
this reason we use the Kmenta approach. For a general presentation of this econometric procedure
see Kmenta (1986) and Greene (2003). The estimation has been performed using the econometric
software “STATA8”.
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population (DPOPi), the mortality rate amenable to health care (MORi)12, and the
poverty rate (POVi)13. In this case, a two-stage least squares approach is applied.
Since data on most explanatory variables are limited to four quarters, the inclusion
of lagged prices will restrict the number of observations available for the estimation.
Model 2 and Model 3 are then estimated by using antibiotic sales for only three
quarters.
3.2 The data
The data for the estimation of equation (2) were obtained from three sources. Infor-
mation on the per capita income, physicians’ density, demographic structure of the
population, the share of foreign people, the level of education, the number of campy-
lobacter infections and the poverty rate were extracted from yearly publications by
the Swiss Federal Statistical Oﬃce. Mortality amenable to health care was obtained
from the Department of Health of the Canton Ticino. Data on antibiotic sales and
prices were provided by IHA-IMS Health Market Research. The data set includes
aggregate outpatient antibiotic expenditure and quantities of diﬀerent classes of an-
tibiotics for Switzerland. Quarterly data were available for three years (2002-2004)
and detailed at cantonal level. For privacy reasons five small cantons have been ag-
gregated to obtain two ”macro” cantons in the dataset so that the total number of
12The rate is defined as the proportion of ”untimely and unnecessary” deaths in the total popu-
lation from diseases for which eﬀective health care is available (Rutstein et al., 1976). The rate for
Swiss cantons is derived by the Department of Health of the Canton Ticino following the method
applied by Nolte and McKee (2003).
13The poverty rate indicates the proportion of individuals below the ”poverty threshold” over the
population of residents. The ”poverty threshold” is defined by a level of total income according to
the rules of the CSIAS (Conférence suisse des institutions d’action sociale). Its current amount is
CHF 1800 (1161) for a household of only one individual.
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cantons was reduced to 23 instead of 26.14
Data on antibiotic sales derives from transactions between wholesalers and phar-
macies and physicians in Switzerland. Since the retailers’ stock of drugs is roughly
constant over time, wholesales data provide a good estimation of outpatient antibi-
otic consumption in the country. However, our data may slightly underestimate total
sales for three main reasons. First, data collected for ambulatory care at least par-
tially exclude drugs delivered in nursing home facilities.15 Second, errors in data
collection measurements may account for approximately 5% of the data which are
missing. Third, since the aim of our analysis is to focus on ambulatory care, few
antibiotic classes mainly related to hospital care (representing less than 2% of the
data) were excluded from the purchased data set.
The data set is also detailed at product/brand and eventually package levels.
Pharmaceutical companies generally provide drug packages standardized for the whole
federal territory.16
The data were available on a specific software, “ORACLE sales Analyser”, having
a multidimensional cube structure: the product, the region, the time period, the
channel of sales and measures of consumption. The data set was partially exported
into MS Excel and STATA8 formats to perform the analysis.
14The dataset could not provide detailed information for areas with less than 5 pharmacies and/or
drugstores. Hence, some small cantons were merged. Uri, Obvalden and Nidwalden were grouped
together and included in Obwalden (OW), whereas Appenzell Outer-Rhodes and Appenzell Inner-
Rhodes were included in Appenzell Rhodes (AR).
15In Switzerland around 50% of nursing homes have an internal pharmacy unit. Antibiotics deliv-
ered by the internal pharmacy are not included in the dataset and counted as hospital consumption.
16However, since diﬀerent types of packages could also be sold in diﬀerent proportions among geo-
graphical areas, we randomly compared the shares of packages sales for main categories of products
across cantons by means of the coeﬃcient of variation. The value was fairly low and very close to
zero for most types of packages.
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The Anatomical Classification (AC-system) provided by the European Pharma-
ceutical Market Research Association (EphMRA) classifies drugs into 16 groups at
three or four levels with an alpha-numeric coding structure. All anti-bacterial agents
(antibiotics) are identified by the alpha-numeric code J01. Antibiotics were dis-
aggregated into diﬀerent classes (for example, J01F macrolides) to investigate the
consumption structure in section 2. Because the classification system of EphMRA
does not perfectly match the international one, we rearranged some of the classes
to obtain the standard antibiotic classes commonly used in international studies17.
In particular, according to the EphMRA classification, broad spectrum penicillins
(coded J01C) and medium and narrow spectrum penicillins (coded J01H) define two
separate groups but have been grouped together in the ATC classification (J01 C peni-
cillins). Quinolones are included in class M in the ATC international classification,
whereas they fill class G for EphMRA. We finally summarized seven diﬀerent classes
: J01 A tetracyclines, J01 C penicillins, J01 D cephalosporins, J01 F macrolides, J01
M quinolones, J01 E sulfonamides and others.
Antibiotic sales are measured in terms of currency units (CHF) and the number of
sold packages. Furthermore, the data set provides a third measure named Counting
Units (CU). CU are defined in terms of milligrams and days of treatment (DOT).
DOT are derived from milligrams using the total number of sold packages, the mil-
ligrams per package and the defined daily dosage (DDD) as DOT = (Number of
packages)(mg. per package)/DDD. The latter measure, according to the WHO18, is
17The ATC classification used in international studies is an extension of the EphMRA classification
suggested by Norwegian researchers in the 1970s. Since 1996, the use of the ATC and, more generally,
of the ATC/DDD system is recognized by the WHO as the international standard.
18This is a constant for each active pharmaceutical ingredient. As the WHO emphasized, the
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the assumed average maintenance dose per day for a drug used for its main indica-
tion in (by) adults. For some products like Penicillins, the standard counting unit is
not the milligrams but the International Unit (IU) established by the UK National
Institute for Medical Research. Hence, we adapted the above expression to consider
IU instead of milligrams.
In addition to the original variables we calculated total per capita sales and days
of treatment per 1000 inhabitants per day (DID) using demographic data at cantonal
level. The latter measure constitutes the explained variable in all the three economet-
ric models defined above. Since daily doses are standardized, our variable assumes
that cantonal variations may be related to two main sources: the number of antibiotic
treatments per 1000 inhabitants per period and the average dosage schedule for each
treatment.
Since many explanatory variables were available for 2002 only, we estimated equa-
tion (2) by using four quarters. Because of the inclusion of lagged prices, Model 2
andModel 3 are instead estimated by using three quarters. As an exception, the level
of education (EDU) refers to year 2000. Table 1 gives summary statistics of variables
included in the models.
3.3 Estimation results
The parameter estimates of the three model specifications are summarized in table
2. All of the models give satisfactory and stable results. In the first model (Model
1) price and infections endogeneity is not addressed. Model 2 includes lags of prices
DDD is a unit of measurement and does not necessarily reflect the recommended or the prescribed
daily dose". For example, doses may depend on individual characteristics such as age and weight.
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Variables Unit of measurement Min. Med. Max.
Outpatient antibiotic DDDs per 1000 4.28 7.89 18.49
consumption (DID) inhabitants per day
Income per capita (Y) Income (CHF)/pop. 35952 45746 77583
Price of a daily dose (P) ales (CHF)/DDDs 3.40 3.72 4.32
Physicians’ density (DPH) Physicians/100000 inhab. 118 160 353
Population under 20 (UNDER20) Under 20/pop. 0.17 0.24 0.26
Population age over 65 (OVER65) Over 65/pop. 0.12 0.15 0.21
Share of foreign population (FO) Foreign people/pop. 0.09 0.19 0.38
Percentage of people without Basic education/pop. 0.19 0.24 0.32
post-mandatory education (EDU)
Incidence of campylobacter Number/100000 inhab. 92 115 187.7
infections (INF)
Density of population (DPOP) Inhabitants/km2 27 218 5149
Poverty rate (POV) Proportion of pop. 0.001 0.170 0.237
below wealth threshold
Mortality rate (MOR) Mortality rate amenable 22.39 29.81 34.807
to health care
Table 1: Variables notation and summary statistics
and the number of infections although observations are restricted to three quarters.
The results are presented for both OLS and GLS estimation procedures. Moreover,
we estimated the model by using OLS and report the Huber/White standard errors.
Finally, Model 3 is estimated by using two stage least squares. However, according
to the Hausman test the null hypothesis of exogeneity cannot be rejected (p=0.85 ).
The majority of the coeﬃcients are significantly diﬀerent from zero and carry the
expected sign in all the models. Each model accounts for more than 80% of observed
cantonal variations in outpatient antibiotic DID. As for the interpretation of the
results, some common points across the alternative specifications can be summarized.
The income coeﬃcient is always very significant and shows a negative sign. This
suggests that richer cantons generally spend less on outpatient antibiotics compared
to lower-income cantons. Since per capita antibiotic sales and regressors are in log-
arithm form, the coeﬃcients can be interpreted as elasticities. The responsiveness
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of the outpatient antibiotic DID to a change in the average cantonal income, ceteris
paribus, is around 0.5 in all of the specifications. This result suggests that anti-
infectives may not be as strongly normal goods as argued by Baye et al. (1997),
whose calculated income elasticity was 1.331. Diﬀerences may be related at least to
three main reasons: the population under study, the time period considered, and the
source of data. First, our analysis focuses on Swiss outpatient antibiotic expenditure
whereas Baye et al. use USA data. The results may then suggest that the Swiss
population is more keen on substituting antibiotics with alternative treatments when
income increases. Findings may also imply that the Swiss population is more aware
of the perverse eﬀects of antibiotic consumption induced by bacterial resistance. This
explanation can be supported by the relatively low per capita antibiotic consumption
in Switzerland compared to other countries. Second, Baye et al.’s study is based upon
1984-1990 data. The raising concern over the impact of antibiotic resistance over the
‘90s may have reduced the income elasticity of outpatient antibiotic expenditure over
time thus leading to our lower elasticity value. Finally, Baye et al. use retailing pre-
scription data collected through surveys of a sample of pharmacies. Instead, we use
total outpatient antibiotic wholesales to pharmacies, drugstores and medical prac-
tices. Our data may not capture the eﬀect of retailing strategies associated with
income because they are not directly related to the final consumer.
The level of education is negatively related to the per capita outpatient antibi-
otic expenditure defined in DID. The coeﬃcient is significant at less than 0.05 in
all the regressions and shows that an increase in the percentage of people without
post-mandatory education increases the per capita antibiotic expenditure defined in
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DID. Education elasticities range from 0.317 to 0.442. To our knowledge there are
not comparable multivariate studies on the impact of education on the use of outpa-
tient antibiotics. A comparison with the literature on medical care utilization, such
as physician oﬃce visits or hospital services, suggests that antibiotics are quite pecu-
liar, as expected. Hunt-McCool et al. (1994) found positive education elasticity to
physician oﬃce visits and hospital care, although the impact is not very significant.
The same kind of impact may not be expected for outpatient antibiotic use where
the association between increasing consumption and the reduced eﬀectiveness due to
resistance may induce more informed individuals to restrain from antibiotic utiliza-
tion. Lleras-Muney and Lichtenberg (2002) found that highly educated people are
generally more likely to use drugs more recently approved by the Food and Drug Ad-
ministration, with the exception of some disease categories such as infectious diseases
where antibiotics are generally consumed.
In terms of the investment in health function in the Grossman model the results
suggest that relatively rich and highly educated people either use health care inputs
(antibiotics) more eﬃciently or have higher initial health stocks. Higher levels of
productivity imply that the same amount of health investment can be obtained by
a lower amount of health care services. Also, higher initial health stocks imply that
lower investment in health, and hence in health care inputs, are required for any given
level of optimal health stocks, ceteris paribus.
As expected the price of a daily dose has a negative and slightly significant impact
on antibiotic sales. Price elasticities range from −0.561 (GLS of Model 1 ) to −0.606
in the lagged model (Model 2 ). Swiss consumers directly bear only a small fraction of
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the total cost of drugs because of compulsory health insurance purchasing. However,
antibiotic sales my be aﬀected by price changes because of standardized deductibles
and copayments. On the other hand, the demand for antibiotics may be more in-
elastic compared to other types of drugs since antibiotics are generally purchased
under doctor’s prescription. Our estimates are slightly lower than those of Baye et
al. (1997) who found negative compensated (−0.785) and uncompensated (−0.916)
own-price eﬀects for anti-infectives. Still, they may support their argument that
anti-infectives have the largest own-price elasticities among all major pharmaceutical
classes. Focusing on the demand for one antibiotic class, the cephalosporins, Elli-
son et al. (1997) calculated own-price elasticities for diﬀerent brand/generic names
unconditional on drug expenditure and using US wholesale data from 1985 to 1991.
Their estimates range from −0.38 to −4.34. Our results could also be compared
to the ones found in Rudholm (2003) who derives own-price elasticities for three
Swedish pharmaceuticals submarkets during the years 1989-1996. The prescription
drug market for beta-receptor blocking agents is maybe the closest to our outpatient
antibiotic market, although not exactly the same. Mean own-price elasticities calcu-
lated by Rudholm are also negative and significant at 5% level ranging between −0.12
to −3.43. A shorter range (from −1.62 to −2.13) is covered by elasticities estimated
by Rizzo (1999) using wholesales data from the US antihypertensive drug market.
An increase in the number of physicians at cantonal level causes an increase in the
cantonal per capita antibiotic DID. The coeﬃcients of physicians’ density are posi-
tive and highly significant. Estimated elasticities are also very stable across diﬀerent
model specifications ranging from 0.543 to 0.680. This result may suggest some evi-
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dence of supply-induced demand in the Swiss market for outpatient anti-infectives.19
Note that antibiotics should only be purchased under physician’s prescription. Under
the assumption that the mismatching between wholesale figures and physicians’ pre-
scriptions can be ignored, our findings may support the hypothesis that physicians do
not act as perfect agents for consumers.20 This is also in accordance with the health
economics literature suggesting that in systems where physicians are paid under a
fee-for-service scheme, akin to the Swiss one, overconsumption of drugs is more likely.
Given that daily doses are standardized, our result suggests that cantonal variations
in physician’s practices may either take the form of diﬀerences in the number of an-
tibiotic treatments per person or diﬀerences in daily dosage schedule. A diﬀerent
result to ours is obtained by Di Matteo and Grootendorst (2002) who estimate the
socioeconomic and demographic determinants of real per capita Canadian provincial
government drug expenditure. In their study the per capita number of prescribing
physicians is found to be a negative, although not a significant, determinant of the
Canadian drug expenditure. However, it is important to point out that the health
care system under investigation exhibits substantial diﬀerences compared to the Swiss
one.
To capture the eﬀects of demography on antibiotic sales we included as covariates
the proportions of the population aged below 20 and over 65. One might expect a
drug expenditure decline during the first few years of life followed by an increase as
the population ages. The literature on the determinants of health care expenditure
19For an exhaustive discussion on the supplier induced demand theory see McGuire (2000).
20This means that physicians may not choose the same doses or type of antibiotic as the patient
would if he/she was as much informed as the physician.
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generally suggests that the increasing prevalence of chronic health problems as peo-
ple grow older may determine an increase in the utilization of health care services.
For instance, Di Matteo and Di Matteo (1998) investigated the determinants of the
real per capital provincial government health expenditure in Canada using a log-log
functional form. They calculated a 0.81 elasticity of the proportion of the popula-
tion aged over 65. In a similar study Di Matteo and Grootendorst found a slightly
significant increase in drug expenditure as the population ages until 64. Between 64
and 74 the eﬀect is still positive although this result is not confirmed by the more
recent study by Di Matteo (2005). We argue, however, that the consumption of anti-
infectives in the community may be quite diﬀerent from other health care services
and consequently does not follow the same trend over the life-time. First, doctors and
patients might be more concerned about the potential harmful eﬀect of prescribing
antibiotics to very young and elderly individuals. Antibiotic treatment is more likely
to be delayed for these individual categories to avoid resistance implications. Sec-
ond, the antibiotic therapy may sometimes be conceived as a time-saving choice and
hence more likely to be adopted by individuals belonging to the labor forces. These
hypothesis are in accordance with the results of a French study conducted on a panel
of general practitioners and focusing on antibiotic prescriptions for rhynopharingeal
infections (Mousquès et al., 2003). Antibiotics are less likely to be prescribed to the
population class aged below 16 compared to the 40-64 population class. On the other
hand, individuals over 64 are less likely to get an antibiotic prescription. Similarly,
we obtained negative and significant coeﬃcients of the proportion of individuals over
65 (from −0.667 to −1.027). We also found a negative impact of the proportion of
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the population aged under 20 on the per capita antibiotic DID. However, this result
is not significant.
Another important factor that may be related to diﬀerences in outpatient an-
tibiotic expenditure across Swiss cantons are the cultural and linguistic variations.
One can argue that cantons adjacent to countries such as France, Germany and Italy
could share similar cultural attitudes for at least two reasons. First, the public per-
ception of the need for antibiotics may be influenced by the perception of neighboring
populations. Second, cantonal “medical attitudes” to prescribing may be influenced
by “medical attitudes” in neighboring countries. These hypothesis are worth testing
also in the light of diﬀerences observed in antibiotic consumption between adjacent
countries (Goossens et al., 2005). Both cultural covariates introduced in our models
exhibit significant coeﬃcients. The share of foreign people on the total population
increases the cantonal per capita outpatient antibiotic expenditure. This result was
expected because of the lower Swiss antibiotic consumption compared to adjacent
countries. The “latin” dummy suggests that antibiotic expenditure is higher in French
and Italian speaking cantons compared to German speaking cantons, which is also in
accordance with the hypothesis above.
The number of infections is significant at less than 5% level both in the lagged
and in the two-stage least squares specifications. Coeﬃcients exhibit the expected
positive sign and suggest that outpatient antibiotic expenditure is not much elastic
to the impact of epidemiological factors. Looking at the pharmaceutical consumption
for cardiovascular disease and stroke, Dickson and Jacobzone (2003) found that drug
use may be strongly related to indicators of the burden of disease for more eﬀective
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Model 1 Model 2 Model 3
OLS GLS OLS GLS 2SLS
Obs. 92 69 69
(Adj.) R2 0.887 0.90 0.894
Coeﬀ . Robust S.E . Coeﬀ . S .E . Coeﬀ . Robust S .E . Coeﬀ . S .E . Coeﬀ . S .E .
Constant 0.383 1.394 2.636b 1.160 1.146 1.191 2.404c 0.770 1.644 1.381
Y -0.509d 0.108 -0 .515d 0.098 -0 .477d 0.100 -0 .490d 0.071 -0 .519d 0.114
Pt -0 .595a 0.326 -0 .561c 0.198 - - - - - -
Pt−1 - - - - -0 .606
a 0.331 -0 .570d 0.178 -0 .564a 0.295
DPH 0.680d 0.111 0.543d 0.100 0.629d 0.116 0.613d 0.073 0.650d 0.110
UNDER20 -0.372 0.261 -0 .054 0.246 -0 .350 0.281 -0 .004 0.181 -0 .257 0.275
OVER65 -1.027d 0.220 -0 .691d 0.211 -0 .885d 0.212 -0 .667d 0.136 -0 .864d 0.179
FO 0.186c 0.064 0.246d 0.057 0.194d 0.057 0.264d 0.041 0.221b 0.060
EDU 0.442c 0.165 0.168 0.143 0.318b 0.162 0.317c 0.101 0.350b 0.133
INF 0.201c 0.084 0.312d 0.066 - - - - 0 .157b 0.078
MEANINF - - - - 0 .172b 0.085 0.164d 0.045 - -
DLATIN 0.173d 0.042 0.220d 0.043 0.171d 0.045 0.153d 0.031 0.154c 0.049
DT1 0.077
b 0.037 0.073d 0.014 - - - - - -
DT2 -0 .205
d 0.027 -0 .206d 0.014 -0 .171d 0.029 -0 .176d 0.015 -0 .173d 0.028
DT3 -0 .178
d 0.027 -0 .184d 0.011 -0 .166d 0.027 -0 .180d 0.013 -0 .166d 0.026
asign ifi cant at 10% , b sign ifi cant at 5% , csign ifi cant at 1% , dsign ifi cant at 0.1% ,
Table 2: Parameter estimates for the three models.
and inexpensive types of drugs only. It is important to point out that the lack of
quarterly data on the prevalence of bacterial infections in our dataset may dilute the
seasonal impact on antibiotic consumption. Seasonal eﬀects are then captured by
time dummies.
Time dummies clearly suggest that there are some seasonal eﬀects in antibiotic
consumption in ambulatory care. The baseline season is represented by the third
quarter, i.e. the autumn dummy (October, November, December). Per capita out-
patient antibiotic DID are expected to be higher during the fourth quarter, winter
(January, February, March), and lower in the first and the second quarter of the year,
as pointed out by Goossens et al.. Accordingly, the estimated coeﬃcients of DT2 and
DT3 are both negative and highly significant in all the three models. The winter
dummy appears in Model 1. This is positive and significant at less than 5% level.
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4 Conclusions
The investigation of regional variations in outpatient antibiotic use may help to under-
stand the determinants of the demand for antibiotics and contribute to the discussion
on the reduction of antibiotic resistance. There is a lack of empirical evidence in the
analysis of within country variations in outpatient antibiotic consumption. Wide dif-
ferences in the utilization of drugs were observed, for instance, between three major
urban areas in Sweden (Wessling et al. 1991).
We analysed cantonal outpatient antibiotic sales in Switzerland. We showed that
the country uses relatively low volumes of antibiotics in ambulatory care compared
to other European countries. In terms of consumption structure, Switzerland is char-
acterized by high proportions of quinolones.
Antibiotic use in ambulatory care significantly increased in terms of defined daily
doses per 1000 inhabitants daily and sales per capita between 2002 and 2003 in most
Swiss cantons. Conversely, consumption generally decreased in 2004.
The investigation of cantonal diﬀerences showed that there are wide variations
across cantons. These can hardly be explained by epidemiological factors only. Econo-
metric estimations on quarterly data for 2002 suggested that per capita income, price,
demographic factors, including the proportion of foreign residents, the density of
medical practices, and cultural and educational diﬀerences may contribute to explain
regional variations in ambulatory antibiotic use.
More eﬀective policies to improve the eﬃcient use of antibiotics in the community
may be driven by these findings. Appropriate incentives aﬀecting antibiotic consump-
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tion and, consequently, levels of bacterial resistance can be designed by looking at
crucial determinants suggested in the model and their relative impact. A number of
studies suggest, for instance, that inappropriate individual consumption is associated
with the lack of awareness of the danger of antibiotic use (Mazzaglia et al., 1999;
Vanden Eng et al., 2003). We showed that higher level of education may account for
lower antibiotic use in the community. Cantonal educational eﬀorts are then needed
if the consumption of antibiotics is to be reduced. Moreover, local guidelines could
represent a valid tool given the evidence that per capita antibiotic consumption is
associated with the density of general practices. The cantonal public health author-
ities should then promote local guidelines with adequate incentives for doctors and
eﬀective information campaigns for appropriate antibiotic use.
Econometric models using data at local level and the application of multiple-choice
models to selected categories of antibiotics should be explored to further explain small
area variations in outpatient antibiotic use. Additional suspicious determinants like
bacterial resistance and prescribing practices should also be considered.
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